Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BN 104

Next Previous
X
Search
Drug Profile

BN 104

Alternative Names: BN-104; BNM-1192

Latest Information Update: 15 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioNova Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Menin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia; Precursor B-cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 15 Feb 2024 BN 104 receives Fast track status from the US FDA for Acute leukemia (Second-line therapy or greater) (greater) (BioNova Pharmaceuticals pipeline, February 2024)
  • 15 Feb 2024 National Medical Products Administration (NMPA) approves IND application for BN 104 in Acute leukaemia (Second-line therapy or greater) (BioNova Pharmaceuticals pipeline, February 2024)
  • 25 Sep 2023 BioNova Pharmaceuticals plans a phase I/II trial for Acute myeloid leukaemia and Precursor cell lymphoblastic leukaemia lymphoma (Second-line therapy or greater) (PO) in October 2023 (NCT06052813)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top